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ABSTRACT 
A liquid chromatography–electrospray ionization–tandem mass spectrometry (LC–ESI–MS/MS) method for the simultaneous 
quantitation of lumefantrine (LF) and its active metabolite, desbutyl lumefantrine (DBL) metabolite in human plasma is developed 
and validated. The chromatographic separation was carried out on Hypersil Gold C18 (50 × 4.6 mm, 5 µm) using 5.0 mM ammonium 
formate (pH 3.0 adjusted with formic acid): acetonitrile (10:90, v/v) as the mobile phase. For sample preparation, solid phase 
extraction was carried out using artemisinin as the internal standard (IS) from 100 µL human plasma. Quantitation of analytes was 
done by tandem mass spectrometer using electrospray ionization in the positive mode. The precursor to product ion transitions 
monitored were m/z 530.5→ 512.1, m/z 472.7→512.1 and m/z 300.2 →219.5 for LF, DBL and IS respectively. The calibration curve 
was linear over the concentration range of 5.0–5000 ng/mL for both the analytes with a correlation coefficient (r2) ≥ 0.9992. The 
intra-day and inter-day assay precision ranged from 1.77 to 7.22 % and 0.96 to 3.90 % for LF and 2.36 to 8.12 % and 0.57 to 4.64 % 
for DBL respectively. Similarly, the intra-day and inter-day assay accuracy was between 98.3–101.2 % and 98.8–102.1 % for LF and 
97.5–101.6 % and 98.2–101.7 % for DBL respectively. The mean extraction recovery of LF and DBL was 98.5 % and 98.4 % across 
four quality control levels. Stability study in plasma was evaluated under different conditions like bench top, auto sampler, 
freeze-thaw and long term. The application of this assay was demonstrated through a bioequivalence with 12 healthy subjects using 
20/120 mg artemether/lumefantrine tablet formulation. 
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INTRODUCTION:  
Malaria is a foremost cause of morbidity and mortality in the 
developing regions of the world and remains the leading health 
issue in endemic regions [1]. Lumefantrine (LF) is a 
2,4,7,9-substituited fluorene (2,3-benzindene) derivative and is 
commercially available in combination with artemether as 
Co-artemether (Riamet®). This artemisinin based combination 
therapy (ACT) has proved to be highly effective for the treatment 
of uncomplicated falciparum malaria in children and adults [2]. In 
addition, LF shows marked blood schizontocidal activity against 
wide range of Plasmodium including Plasmodium falciparum. 
Biochemical studies have revealed that the anti-malarial action of 
LF involves lysosomal trapping of the drug in the food vacuole of 
the intra-erthrocytic parasite, followed by binding to haem. Thus, 
the polymerization of haem is prevented and thereby inhibiting the 
detoxification of haem [3]. LF is mainly metabolized (to a low 
extent) by liver microsomal cytochrome P450 isoenzyme 3A4 into 
its putative metabolite desbutyl lumefantrine (DBL) [4]. LF is a 
highly lipophilic in nature and its human serum protein binding is 
about 99 %. The maximum plasma concentration is attained 
within 6-7 h. LF has a much longer elimination half-life (several 
days) and is associated with a low recrudescence rate, but has a 
slower onset of action.The elimination half-life of DBL is longer 
than LF [2, 4-5]. 
 Literature presents several methods to quantify LF as a single 
analyte [6-12] in different biological matrices like rat plasma [6], 
mouse whole blood [7], dried blood spots [8, 9], human plasma 
[10-12]. Simultaneous analysis of LF together with DBL in human 
plasma [13-18] and with other anti-malarial or anti-retroviral 
drugs [19-21] is also reported. In these methods analytical 
techniques like HPLC with UV/fluorescence [8, 9, 11, 13, 15, 17, 
20, 21] and mass spectrometric detection [6, 7, 10, 12, 14, 16, 18, 
19] have been employed. The salient features of methods for the 
simultaneous quantification of LF and DBL in human plasma are 
summarized in Table 1. 
In the present work we report an improved LC-MS/MS method for 
determination of LF and DBL in human plasma with respect to the 
sensitivity, analysis time and plasma sample volume over existing 
methods. The method was applied to a bioequivalence study in 12 
healthy subjects using 20/120 mg artemether/lumefantrine tablet 
formulation.     
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Table 1 Comparative assessment of chromatographic methods developed for lumefantrine and desbutyl lumefantrine in human plasma 
Sr. 
No. 
Technique; 
linear  
range (ng/mL) 
Extraction 
procedure; 
plasma volume 
(µL) 
Retention time 
LF/DBL; run 
time (min) 
Application Ref. 
1 HPLC-UV; 
24-20,000 for LF 
and 21-1010 for 
DBL  
SPE; 250 
 
16.5/10.0; 25.0 Analysis of LF from plasma samples 
obtained from clinical trials of 
artemether-lumefantrine  
13 
2 HPLC-UV; 
12-12000 for both 
the analytes  
LLE; 200 
 
7.25/4.86; 10.0 Measurement of LF and DBL in plasma 
samples of patients 
15 
3 HPLC-UV; 
10-12000 for both 
the analytes 
LLE; 200 
 
2.7 and 6.1; 10.0 The method was applied for determination 
of LF and DBL concentrations in a 
pharmacokinetic food-drug interaction 
study 
17 
4 LC-MS/MS; 
4-4000 
PP; 200 
 
15.0/13.1; 17.0 Simultaneous determination of 14 
antimalarial drugs and their metabolites in 
human plasma 
14 
5 LC-MS/MS; 
2.0-2000 for both 
analytes 
PP followed by 
SPE; 100 
 
8.28/7.20;  
9.0 
The method was applied to determine LF 
and DBL in 24 patients 
16 
6 LC-MS/MS; 
21-529 for LF and 
1.9-47 for DBL  
PP; 100 
 
1.7/1.5;  
2.2 
The method was applied to determine 
plasma LF and DBL concentration in 
children under 5 years of age 
18 
7 LC-MS/MS; 
5.0-5000 for both 
the analytes 
SPE; 100 1.81/0.90; 2.50 Bioequivalence study with 20/120 mg 
tablet formulations of 
artemether/lumefantrine in 12 healthy 
volunteers 
PM 
LF: lumefantrine; DBL: desbutyl lumefantrine; PP: protein precipitation; LLE: liquid-liquid extraction;  
SPE: solid phase extraction; PM: present method 
 
EXPERIMENTAL 
Chemicals and materials 
Reference standards of lumefantrine (LF, 98.14%), desbutyl 
lumefantrine (DBL, 99.52%) and artemisinin (IS) (ARM, 
99.33%) were procured from Clearsynth Labs (P) Ltd. (Mumbai, 
India). HPLC grade methanol and acetonitrile were obtained from 
Mallinckrodt Baker, (S.A.de C.V. Mexico). Guaranteed reagent 
grade formic acid and ammonium formate were obtained from 
Merck Specialties Pvt. Ltd., (Mumbai, India). Water used in the 
entire analysis was prepared from Milli-Q water purification 
system procured from Millipore (Bangalore, India). Oasis HLB 
extraction cartridges (30 mg/1 mL) were purchased from Waters 
(Bangalore, India). Blank human plasma was procured from 
Supratech Micropath (Ahmedabad, India) and was stored at -20 
°C until use. 
Optimized liquid chromatography and mass spectrometry 
conditions  
A Shimadzu HPLC system (Kyoto, Japan) equipped with 
LC-20AD pump was used for the separation of the analytes on a 
Thermo Scientific Hypersil Gold C18 (50 × 4.6 mm, 5 µm) 
column, maintained at 40 °C in a column oven. The mobile phase 
consisted of 5.0 mM ammonium formate, (pH 3.0 adjusted with 
formic acid): acetonitrile (10:90, v/v) and was delivered at the 
flow rate of 1.0 mL/min. Detection of analytes and IS was 
performed on a triple quadrupole mass spectrometer, API-4000 
equipped withTurbo Ion spray®, manufactured by MDS SCIEX 
(Toronto, Ont., Canada) and operating in the positive ionization 
mode. For the analytes and IS the source dependant parameters 
maintained were Gas 1 (Nebulizer gas): 15 psi, Gas 2 (heater gas): 
10 psi, ion spray voltage (ISV): 5000 V, turbo heater temperature: 
400 °C, entrance potential: 5.0 V, collision activation dissociation: 
10 psi and curtain gas: 20 psi. The compound dependent 
parameters like declustering potential, collision energy and cell 
exit potential were optimized at 70 V, 40 eV and 9 V for the 
analytes and 75 V, 45 eV and 12 V for IS respectively. 
Quadrupole 1 and 3 were maintained at unit mass resolution and 
the dwell time was set at 100 ms. Analyst software version 1.4.2 
was used to control all parameters of LC and MS. 
Standard stock, calibration standards and quality control 
samples 
The stock standard solutions of LF and DBL were prepared by 
dissolving their accurately weighted compounds in methanol to 
give a final concentration of 200 μg/mL. Further, intermediate 
solutions (100.0 µg/mL and 50.0 µg/mL) for spiking were 
prepared in methanol: water (60:40, v/v). All the solutions were 
stored at 2–8 °C and were brought to room temperature before use. 
The calibration standards (CSs) and quality control (QC) samples 
were prepared by spiking (5%) blank plasma with standard 
working solutions. CSs were made at concentration of 5.00, 10.0, 
25.0, 50.0, 100.0, 300.0, 600.0, 1200, 2500 and 5000 ng/mL for 
both the analytes. QC samples were prepared at four different 
concentration levels, 5.000 (LLOQ, lower limit of quantification 
quality control), 15.00 (LQC, low quality control), 1000/200.0 
(MQC-1/2, medium quality control) and 3500 ng/mL (HQC, high 
quality control). Stock solution (100.0 µg/mL) of the IS was 
prepared by dissolving 1.0 mg of artemisinin in 10.0 mL 
methanol. Its working solution (100 ng/mL) was prepared by 
appropriate dilution of the stock solution in methanol:water 
(60:40, v/v). All standard stock and working solutions used for 
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spiking were stored at 5 °C, while CSs and QC samples in plasma 
were kept at -70 °C until use.  
Protocol for sample preparation 
All frozen subject samples, CSs and QC samples were thawed at 
room temperature prior to analysis. The samples were adequately 
vortexed for 10 s. An aliquot of 100 µL plasma sample was mixed 
with 25 μL of IS. The mixture was vortexed for 2 min, followed by 
centrifugation at 14000 × g for 5 min at 10 °C. The supernatant 
was loaded on SPE cartridges which were pre-conditioned with 
1.0 mL of methanol followed by 1.0 mL of water. Subsequently, 
the cartridges were washed with 2.0 mL water and then dried for 
2.0 min by applying 1.72 × 105 Pa pressure at 2.4 L/min flow rate 
of nitrogen. Elution of analytes and IS from the cartridges was 
carried out with 100 µL of mobile phase and 5 µL of eluate was 
used for injection in the LC–MS/MS system. 
Method validation procedures 
The method was validated as per the current regulatory 
requirements to establish the accuracy and precision of the method 
[22]. The parameters studied were similar to our previous work 
[23] and are described in brief.  
System suitability experiment was performed by injecting six 
consecutive injections using aqueous standard mixture of analytes 
and IS at the start of each batch during method validation. System 
performance was studied by injecting one extracted blank 
(without analytes and IS) and one extracted LLOQ sample with IS 
at the beginning of each analytical batch. Autosampler carryover 
was evaluated by sequentially injecting extracted blank plasma → 
ULOQ sample → two extracted blank plasma sample → LLOQ 
sample → extracted blank plasma at the start and end of each 
batch. 
Selectivity of the method was assessed for potential matrix 
interferences in ten batches (6 normal lots of K3EDTA, 2 
haemolysed, and 2 lipemic) of blank human plasma by extraction 
and inspection of the resulting chromatograms for interfering 
peaks. The selectivity of the method toward commonly used 
medications by human volunteers was also ascertained. This 
included paracetamol, ranitidine, diclofenac, caffeine, 
acetylsalicylic acid and ibuprofen. Their stock solutions (100 
μg/mL) were prepared by dissolving requisite amount in 
methanol:water (60:40, v/v). Further, working solutions were 
prepared in the mobile phase and 5 μL was injected to check for 
any possible interference at the retention time of analytes and ISs. 
The cross talk of multiple reaction monitoring (MRM) for 
analytes and IS was checked using highest standard on calibration 
curve and working solution of ISs. 
Five calibration lines containing ten non-zero concentrations were 
used to determine linearity. A quadratic, 1/x2, least-squares 
regression algorithm was used to plot the peak area ratio 
(analyte/IS) from MRM versus concentration. The linear 
equations were then used to calculate the predicted concentrations 
in all samples within the analytical runs. The correlation 
coefficient for each calibration curve must be ≥0.99 for both the 
analytes. Reinjection reproducibility for extracted samples was 
also checked by reinjection of an entire analytical batch after 
storage at 5 °C. 
Intra-day accuracy and precision were evaluated by replicate 
analysis of plasma samples on the same day. The analytical run 
consisted of a calibration curve and six replicates of LLOQ, LQC, 
MQC-1/2 and HQC samples. The inter-day accuracy and 
precision were assessed by analysis of five precision and accuracy 
batches on three consecutive validation days. The precision (% 
CV) at each concentration level from the nominal concentration 
should not be greater than 15%. Similarly, the mean accuracy 
should be within 85–115%, except for the LLOQ where it can be 
within 80–120 % of the nominal concentration [22]. 
Ion suppression/enhancement effects on the MRM LC–MS/MS 
sensitivity were evaluated by post column analyte infusion 
experiment. Briefly, a standard solution containing LF and DBL 
(at MQC-1 level) was infused post column into the mobile phase 
at 10 μL/min employing infusion pump. Aliquots of 5 μL of 
extracted control blank plasma sample were then injected into the 
column by the autosampler and chromatograms were acquired for 
both analytes and IS. 
 Extraction recovery of the analytes and IS from human plasma 
was evaluated in six replicates by comparing the mean peak area 
responses of pre-extraction fortified samples to those of 
post-extraction fortified samples. Matrix effect, expressed as 
matrix factors (MFs) was assessed by comparing the mean area 
response of post-spiked samples with samples prepared in mobile 
phase. IS-normalized MFs (analyte/IS) were calculated to access 
the variability of the assay due to matrix effects. Relative matrix 
effect was assessed from the precision (% CV) values of the slopes 
of the calibration curves prepared from ten different plasma 
sources, which included haemolysed and lipemic plasma. To 
prove the absence of matrix interference the % CV should not be 
greater than 4 %. 
Stock solutions of analytes and IS were checked for short term 
stability at room temperature (25 °C) and long term stability at 5 
°C. Stability results in plasma were evaluated by measuring the 
area ratio response (analyte/IS) of stability samples against freshly 
prepared comparison standards with identical concentration. Auto 
sampler (wet extract), bench top (at room temperature), freeze–
thaw (at −20 °C and −70 °C) and long term stability (at −20 °C and 
−70 °C) was performed at LQC and HQC level using six 
replicates. The stability samples were quantified against freshly 
prepared quality control samples. Stability data were acceptable if 
the % change of the replicate determinations did not exceed 15.0 
% of the nominal value. 
Method ruggedness was verified using two precision and accuracy 
batches. The first batch was analyzed on two different columns of 
the same make but different batch number, while the second batch 
was analyzed by two different analysts who were not part of 
method validation. The ability to dilute samples which could be 
above the upper limit of the calibration range was validated by 
analyzing six replicate samples of 7500 ng/mL and 10000 ng/mL 
concentration for LF and DBL after two- and ten-fold dilution 
respectively. The precision and accuracy for dilution reliability 
was determined by comparing the samples against freshly 
prepared calibration curve standards. 
Bioequivalence study, statistical analysis and incurred sample 
reanalysis 
The bioequivalence study was an open label, balanced, 
randomized, two-treatment, two-period, two-sequence, crossover 
study for a single dose of test (20/120 mg artemether/lumefantrine 
tablets from a Generic Indian Company, India) and reference 
(Coartem® tablets containing 20/120 mg artemether/lumefantrine, 
marketed by Novartis Pharmaceuticals Corporation, East 
Hanover, New Jersey, USA) formulation in 12 healthy adult 
Indian male subjects under fasting. Written consent was taken 
from all the subjects after informing them about the objectives and 
possible risks involved in the study. The study was conducted 
strictly in accordance with guidelines laid down by International 
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Conference on Harmonization and USFDA [24]. The subjects 
were orally administered a single dose of test and reference 
formulations with 240 mL water after recommended wash out 
period of 2 weeks. Blood samples were collected at 0.00 
(pre-dose), 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 5.00, 
5.50, 6.00, 6.50, 7.00, 7.50, 8.00, 8.50, 9.00, 10.0, 12.0, 16.0, 24.0, 
48.0, 72.0, 96.0, 144, 192, and 240 h after oral administration of 
the test and reference formulation in labelled K3EDTA-vacuettes. 
Plasma was separated by centrifugation and kept frozen at −70 °C 
until analysis. During study, subjects had a standard diet while 
water intake was unmonitored. The pharmacokinetic parameters 
were estimated by non-compartmental analysis using WinNonlin® 
software version 5.3 (Pharsight Corporation, Sunnyvale, CA, 
USA). To determine whether the test and reference formulations 
were pharmacokinetically equivalent, Cmax, AUC0–240, and AUC0–
inf and their ratios (test/reference) using log transformed data were 
assessed; their means and 90 % CIs were analyzed by using SAS® 
software version 9.2 (SAS Institute Inc., Cary, NC, USA). The 
drugs were considered pharmacokinetically equivalent if the 
difference between the compared parameters was statistically 
non-significant (P ≥ 0.05) and the 90 % confidence intervals (CI) 
for these parameters fell within 80–125 %. 
RESULT AND DISCUSSION 
Method development  
The electrospray ionization provided superior response over 
atmospheric pressure chemical ionization mode and hence was 
chosen for the present work. In order to optimize ESI conditions 
for LF, DBL and artemisinin (IS), quadrupole full scans were 
carried out in the positive ionization mode. Mass spectrometric 
conditions like collision energy, cone voltage and capillary 
voltage were suitably optimized to obtain maximum sensitivity for 
LF, DBL and IS. The full scan mass spectra for analytes and IS 
predominantly contained precursor [M+H]+ ions at m/z 530.5, 
472.7 and 300.2 respectively. The collision induced dissociation 
mass spectra for LF, DBL and IS revealed most stable and 
consistent daughter ions at m/z 512.1, 454.2, and 219.5 
respectively as shown in Figure 1.  
 
 
Figure 1 Product ion mass spectra of (a) lumefantrine (m/z 530.5 
→ 512.1), (b) desbutyl lumefantrine (m/z 472.7 → 454.2) and (c) 
internal standard, artemisinin (m/z 300.2 → 219.5) in the scan 
range 50-570 amu and in the positive ionization mode. 
Sample preparation is crucial for reliable quantitation of drugs in 
biological samples. Several reported methodologies have adopted 
protein precipitation (PP) [7, 10, 14, 18], liquid-liquid extraction 
(LLE) [6, 11, 12, 15, 16, 20] or solid phase extraction (SPE) [8, 
13] for sample clean-up. Majority of the methods have employed 
LLE for the simultaneous extraction of LF and DBL from human 
plasma. Recently, SPE method has been reported for the 
extraction of LF and DBL from small plasma volume. In the 
present work, extraction trials were carried out using all three 
generic techniques but the recovery obtained from SPE was much 
consistent and quantitative. Lindegårdh et al. [13] used C8 SPE 
column, however, the recovery for LF and DBL from human 
plasma was <75 % while Blessborn et al. [8] perform extraction in 
whole blood. As the goal was to develop a simple and robust 
method, SPE was carried out on Oasis HLB extraction cartridges 
(30 mg/1 mL), which required minimal steps for sample cleanup 
and ensured quantitative and precise recovery at all QC levels for 
the analytes and IS. For sample processing only 100 µL plasma 
sample was used and 5 µL was injected into the chromatographic 
system. 
To set the most favorable chromatographic conditions, different 
buffers like ammonium acetate, ammonium formate in varying 
combinations with methanol/acetonitrile were tried. Low pH 
buffer enhanced protonation and helped in eluting the analytes 
completely without tailing, which assisted in proper quantification 
of analyte peaks. Number of columns including Hypurity C8 (50 × 
4.6 mm, 5 mm), Hypurity Cyano (50 × 4.6 mm, 5 µm), Beta basic 
Cyano (100 × 2.1 mm, 5 µm), BDS Hypersil C18 (50 × 4.6 mm, 5 
µm) and Hypersil Gold C18 (50 × 4.6 mm, 5µm) were evaluated 
during chromatographic trials. The best chromatography was 
achieved on Hypersil Gold C18 (50 × 4.6 mm, 5µm) column, 
which offered well resolved peaks with no peak tailing. The nature 
of mobile phase and its composition, buffer pH and flow rate was 
extensively optimized on this analytical column. The best 
chromatographic conditions were obtained with 5.0 mM 
ammonium formate (pH 3.0, adjusted with 0.1 % formic acid) and 
acetonitrile (10:90, v/v) as the mobile phase at a flow rate of 1.00 
mL/min. These conditions afforded a run time of 2.5 min with 
retention times of 1.81, 0.90 and 1.15 min for LF, DBL and IS 
respectively. The MRM chromatograms are depicted in Figure 
2-4. The capacity factors, which describe the rate at which the 
analytes migrate through the column, were 2.02 and 0.51 for LF 
and DBL respectively, while the resolution factor between the 
analytes was 4.14. The reinjection reproducibility (% CV) of 
retention times for LF and DBL was ≤ 1.11 for one entire batch on 
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the same column. Artemisinin, used as IS in the current work gave 
acceptable results for accuracy and precision at each QC level.  
Assay performance and validation results 
The precision (% CV) of system suitability test was found in the 
range of 0.19–0.42 % for the retention time and 0.91–1.54 % for 
the area response for both the analytes and IS. Similarly, the signal 
to noise ratio for system performance was ≥ 30. There was 
negligible carry over (≤ 0.18 %) during autosampler carryover 
experiment. No enhancement in the response was observed in 
extracted blank plasma (without IS and analytes) following 
injection of highest calibration standard at the retention time of 
both the analytes and IS. 
All five calibration curves were linear over the concentration 
range of 5.000 – 5000 ng/mL for LF and DBL with correlation 
coefficient (r2) ≥ 0.9998. A straight line fit was made through the 
data points by least square regression analysis to give the mean 
linear equation y = (0.00106 ± 0.000035) x  −  (0.000039 ± 
0.000060) and y = (0.00099 ±  0.00001)x  −  (0.000027 ± 
0.000014) for LF and DBL respectively, where y is the peak area 
ratio of the analyte/IS and x the concentration of the analyte. 
 
Figure 2 MRM ion-chromatograms of blank plasma for 
lumefantrine (m/z 530.5 → 512.1), desbutyl lumefantrine (m/z 
472.7 → 454.2) and IS (m/z 300.2 → 219.5). 
 
 
Figure 3 MRM ion-chromatograms of lumefantrine (m/z 530.5 → 
512.1) and desbutyl lumefantrine (m/z 472.7 → 454.2) at LLOQ 
and IS (m/z 300.2 → 219.5). 
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Figure 4 MRM ion-chromatograms of lumefantrine and desbutyl 
lumefantrine in subject sample at Cmax after oral administration of 
20/120 artemether/lumefantrine tablet formulation and 
artemisinin, IS. 
The lowest concentration (LLOQ) in the standard curve was 
5.000ng/mL for both the analytes in plasma at a signal-to-noise 
(S/N) ratio ≥ 30. The accuracy and precision (% CV) observed for 
the calibration curve standards ranged from 96.5 to 103.1 % and 
0.29 to 8.82 % for LF and 97.3 to 105.1 % and 1.03 to 3.69 % for 
DBL, respectively. The analytical method was shown to be 
selective based on absence of any analytical signals at the 
retention time of LF, DBL and IS in ten different batches of blank 
plasma. The intra-batch and inter-batch precision and accuracy 
results were within the stipulated range of ±15 % of the nominal 
concentration and ˂ 15 % CV of the mean values as shown in 
Table 2. 
Table 2 Intra-day and inter-day precision and accuracy for lumefantrine and desbutyl lumefantrine 
Nominal 
conc. 
(ng/mL) 
Intra-day (n = 6; single batch) Inter-day (n = 30; 6 from each batch) 
Mean conc. 
found (ng/mL) 
CV 
(%) 
 
Accuracy 
(%) 
Mean conc. 
found (ng/mL) 
CV 
(%) 
 
Accuracy (%) 
Lumefantrine 
HQC (3500) 3503 2.21 101.2 3573 0.96 102.1 
MQC-1 (1000) 993.4 4.96 100.7 987.8 2.59 98.8 
MQC-2 (200.0) 203.2 1.77 100.2 200.9 1.66 100.4 
LQC (15.00) 14.63 7.22 99.7 14.96 3.88 99.7 
LLOQ QC (5.000) 4.987 6.98 98.3 5.055 3.90 101.1 
Desbutyl lumefantrine 
HQC (3500) 3485 2.61 100.1 3437 0.57 98.2 
MQC-1 (1000) 1030 2.51 99.3 1007 4.64 100.7 
MQC-2 (200.0) 192.6 2.36 101.6 203.4 2.61 101.7 
LQC (15.00) 14.86 5.01 97.5 15.05 3.41 100.3 
LLOQ QC (5.000) 5.084 8.12 99.7 4.952 4.42 99.0 
   CV: Coefficient of variation; n: Number of replicates; HQC: high quality control;  
    MQC: medium quality control; LQC: low quality control; LLOQ QC: lower limit of  
    quantitation quality control 
Table 3 Extraction recovery and matrix factor for lumefantrine and desbutyl lumefantrine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A: mean area response of six replicates prepared by spiking in extracted blank plasma; B: mean area response of six replicates prepared 
by spiking before extraction; C: mean area response of six replicates prepared by spiking in mobile phase (neat samples); IS: internal 
standard, artemisinin; n: number of replicates; LQC: low quality control; MQC: medium quality control; HQC: high quality control. 
 
 
 
QC 
 level 
Area response (replicate,  
n = 6) 
Extraction 
recovery, % (B/A)  
Matrix factor 
A  B  C  Analyte IS Analyte 
 (A/C) 
IS 
 
IS-normalized 
Lumefantrine 
LQC 24122 23559 23147 97.7 96.0 1.04 0.98 1.04 
MQC-2 320587 315874 317985 98.5 97.8 1.01 0.97 1.03 
MQC-1 1513398 1489522 1548836 98.4 97.3 0.98 1.01 0.97 
HQC 5633178 5591221 5640587 99.3 96.9 0.99 1.03 0.96 
Desbutyl lumefantrine 
LQC 20731 20477 19954 98.8 96.0 1.03 0.98 1.06 
MQC-2 279221 271021 275664 97.1 97.8 1.01 0.97 1.04 
MQC-1 1288745 1274439 1306844 98.9 97.3 0.99 1.01 0.98 
HQC 4640545 4592975 4649211 98.9 96.9 0.99 1.03 0.96 
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Matrix effect can be attributed to some undesirable effects that 
originate from a biological matrix. These components may result 
in ion suppression/enhancement, decrease/increase in sensitivity 
of analyte over a period of time, increased baseline, imprecision of 
data, drift in retention time and distortion or tailing of a 
chromatographic output. It is suggested that evaluation of matrix 
factors (MFs) can help to assess the matrix effect. MFs can be 
determined from the peak area response for the analyte and IS 
separately, while the ratio of the two factors yields IS-normalized 
MF. Further, matrix effect needs to be checked in lipemic and 
haemolysed plasma samples in addition to normal K3EDTA 
plasma. The extraction recovery and matrix factors for LF and 
DBL are presented in Table 3. The mean extraction recovery for 
LF, DBL and IS were 98.5, 98.4 and 90.7 % respectively. Further, 
the relative matrix effect expressed as precision (% CV) in the 
measurement of the slopes of the calibration curves was ˂  3.1 % in 
ten different plasma sources. 
Further, qualitative assessment of matrix effect through 
post-column infusion experiment showed no ion suppression or 
enhancement at the retention time of LF, DBL and IS in the 
chromatograms (Figure 5). 
The stability of analyte and IS in human plasma and stock 
solutions was examined under different storage conditions. Stock 
solutions for short term stability of LF, DBL and IS were stable at 
room temperature up to 24 h and between 2-8 °C for a minimum 
period of 30 days. LF and DBL in control human plasma (bench 
top) at room temperature was stable for at least 20 h at 25 °C and 
for minimum of six freeze and thaw cycles. Autosampler 
(processed sample) stability of the spiked quality control samples 
was determined up to 36 h. Long term stability of the spiked 
quality control samples remained unchanged up to 198 days. The 
% change values for different stability experiments at LQC and 
HQC levels in plasma are shown in Table 4. 
 
 
 
 
 
 
Figure 5 Post column analyte infusion MRM LC-MS/MS 
chromatograms for (a) lumefantrine, (b) desbutyl lumefantrine 
and (c) artemisinin. 
The ruggedness of the method was evaluated by re-injection of 
analyzed samples on two Hypersil Gold C18 (50 × 4.6 mm, 5.0 
µm) columns, each from a different batch and also by two 
analysts. The precision (% CV) and accuracy values for different 
columns and analysts ranged from 0.5 to 2.5 % and from 95.1 to 
103.1 % respectively for LF and DBL across five QC levels. The 
dilution integrity experiment was performed with an aim to 
validate the dilution test to be carried out on higher analyte 
concentration above the upper limit of quantification (ULOQ), 
which may be encountered during real subject sample analysis. 
The precision values for dilution reliability for 1/5 and 1/10th 
dilution were within 0.7 to 1.8%, while the accuracy results were 
between 96.3 % and 97.1 % respectively. 
Table 4 Stability results of lumefantrine and desbutyl lumefantrinein plasma under various conditions (n = 6) 
 
Storage conditions 
 
Nominal 
conc. 
(ng/mL) 
Mean stability 
sample  
(ng/mL ± SD) 
Change 
(%) 
Mean stability 
sample  
(ng/mL ± SD) 
Change 
(%) 
  Lumefantrine Desbutyl lumefantrine 
Bench top stability at 25 °C, 
20 h 
3500 3518 ± 75.4  0.51 3476 ± 61.8 -0.66 
15.00 15.15 ± 0.45  0.97 14.79 ± 0.69 -1.38 
Freeze & thaw stability at -20 
°C 
3500 3410 ± 52.3 -2.56 3469 ± 40.4 -0.88 
15.00 14.61 ± 0.32 -2.59 15.93 ± 0.60 6.21 
Freeze & thaw stability at -70 
°C 
3500 3466 ± 50.1 -0.97 3457 ± 68.5 -1.24 
15.00 14.28 ± 0.22 -4.82 14.87 ± 0.79 -0.90 
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Autosampler stability   at 
4°C, 36 h 
3500 3478 ± 61.3 -0.63 3444 ± 66.40 -1.60 
15.00 14.77 ± 0.67 -1.56 14.48 ± 0.96 -3.44 
Long term stability at 
 -20 °C, 198 days 
3500 3145 ± 66.9 -2.44 3477 ± 91.3 -0.65 
15.00 16.31 ± 0.90 8.73 15.34 ± 0.35 2.26 
Long term stability  at  
-70 °C, 198 days 
3500 3435 ± 32.5  -1.85 3519 ± 36.1 0.54 
15.00 14.57 ± 0.50 -2.88 14.35 ± 0.37 -4.36 
SD: standard deviation; n: number of replicates; HQC: high quality control; LQC: low quality control 
100
samples comparisonMean 
samples comparisonMean –  samplesstability Mean 
%Change 
 
 
Application of the method in healthy human subjects 
The validated method was successfully applied for the assay of LF 
and DBL in 12 healthy Indian male subjects. Figure 6 shows the 
plasma concentration vs. time profile for LF and DBL under 
fasting condition.  
 
 
 
 
Figure 6 Mean plasma concentration-time profile of lumefantrine 
and desbutyl lumefantrine after oral administration of test (20/120 
mg tablets from a Generic Indian Company, India) with a 
reference (Coartem® tablets containing 20/120 mg 
artemether/lumefantrine tablets from Novartis Pharmaceuticals 
Corporation, East Hanover, New Jersey, USA) formulation to 12 
healthy subjects. 
 
 
 
Approximately 672 samples including the calibration and QC 
samples with volunteer samples were run and analyzed during a 
period of 5 days and the precision and accuracy for calibration and 
QC samples were well within the acceptable limits. The important 
pharmacokinetic parameters namely, maximum plasma 
concentration (Cmax), area under the plasma concentration-time 
curve from 0 to 240 h (AUC0-240), area under the plasma 
concentration-time curve from zero hour to infinity (AUC0-inf), 
time point of maximum plasma concentration (Tmax), half life of 
drug elimination during the terminal phase (t1/2) and elimination 
rate constant (Kel) were calculated for the test and reference 
formulations and are presented in Table 5. 
Table 5 Mean pharmacokinetic parameters after oral administration of 20/120 mg artemether/ lumefantrine tablet formulation in 12 
healthy Indian subjects under fasting. 
Parameter  Test  
 (Mean ±SD) 
Reference  
(Mean ±SD) 
Ratio (test/reference),% 
Lumefantrine 
Cmax (ng/mL)  1561.25 ± 532.49 1560.66  ± 614.18 100.03 
AUC 0-240 h (h.ng/mL)  83214.9 ± 985.5 79751.0 ± 1021.2 104.34 
AUC 0-inf (h.ng/mL)  89815.5 ± 1009.3 85644.8 ± 1011.8 104.85 
Tmax (h)  7.25 ± 1.45 7.12 ± 1.22 --- 
t1/2 (h)  58.67 ± 15.39 55.71 ± 18.11 --- 
Kel (1/h)  0.0118 ± 0.0090 0.0124 ± 0.0061 --- 
Desbutyl lumefantrine 
Cmax (ng/mL)  3620.21 ± 711.27 3611.13 ± 695.66 100.25 
AUC 0-240 h (h.ng/mL)  275519.9 ± 1055.4 265412.7 ± 1021.1 103.80 
 J. of Advancement in Medical and Life Sciences                  Volume 3 /Issue 4                                                       ISSN: 2348-294X 9 
AUC 0-inf (h.ng/mL)  339125.5 ± 1335.1 327452.2 ± 1524.9 103.56 
Tmax (h)  7.05 ± 1.07 6.90 ± 1.13 --- 
t1/2 (h)  75.85 ± 8.36  72.33 ± 9.39 --- 
Kel (1/h)  0.0092 ± 0.0001 0.0096 ± 0.0002 --- 
 
  SD: standard deviation; CV: coefficient of variation 
 
CONCLUSIONS 
 The bioanalytical methodology developed for the simultaneous 
determination of LF and DBL is highly specific and rugged for 
therapeutic drug monitoring. It can be readily applied for the 
analysis of routine samples with desired sensitivity, precision, 
accuracy and high throughput. The method involved a simple, 
quick, clean and specific sample preparation by solid phase 
extraction. A short analysis time of 2.5 min under isocratic 
conditions ensures higher throughput for subject sample analysis 
compared to reported methods in the literature. The method was 
shown to be selective and free from matrix interference as evident 
from the results of post-column infusion, IS-normalized matrix 
factors and relative matrix effect in different plasma sources. 
Moreover, the established LLOQ is adequate enough to conduct a 
pharmacokinetic study/bioequivalence study with 20/120mg 
formulation of artemether/lumefantrine in healthy human 
volunteers. 
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